Shares of telehealth provider Hims & Hers Health experienced a significant rally on Wednesday, advancing approximately 14% to close at $24.29. The stock reached an intraday high of $25.45 following a regulatory announcement that could reshape its business landscape.
FDA Signals Shift on Peptide Compounds
The catalyst for the move was news that the U.S. Food and Drug Administration plans to reevaluate its restrictions on several peptide compounds. The agency has scheduled an advisory committee meeting for July 23-24 to examine whether compounding pharmacies should be permitted to use seven specific peptides, including BPC-157 and TB-500. In a separate but related development, the FDA indicated it will remove several of these peptides from its Category 2 safety-risk list within seven days, following the withdrawal of their nominations.
This regulatory shift represents a potential turning point for peptide therapies, which faced significant FDA scrutiny last year over concerns regarding toxicity, impurities, and immune responses. That earlier stance led to a shutdown of compounding for many peptide products in 2023.
Strategic Positioning and Market Context
Hims & Hers has been strategically positioning itself in this space. In February 2025, the company acquired a peptide manufacturing facility in California to strengthen its U.S. supply chain. Dr. Pat Carroll, the company's Chief Medical Officer, commented that the FDA's latest position could help move peptide therapy "out of the gray market and into more trusted channels." He added that the company is "actively exploring" opportunities to expand access if future regulatory guidance permits.
The development comes as Hims & Hers has been working to diversify its revenue streams beyond the spotlighted GLP-1 market for weight loss and diabetes. Earlier this spring, the company faced challenges in the compounded semaglutide space, pulling a $49 compounded pill just days after its February launch following an FDA warning about copycat versions. By March, the company pivoted, striking a deal with Novo Nordisk to offer the branded drugs Wegovy and Ozempic on its platform. CEO Andrew Dudum has referred to branded GLP-1s as an area with "tremendous growth opportunities."
Financial Performance and Competitive Landscape
For the 2025 fiscal year, Hims & Hers reported substantial financial results, with revenue reaching $2.35 billion and subscriber count growing to 2.511 million. The company's annual report noted that the majority of its U.S. revenue already originates from segments outside the GLP-1 category. The firm is scheduled to report its first-quarter earnings on May 11, which will provide investors with a fresh look at its financial health and strategic direction.
As regulatory pressures increase in the compounded drug space, Hims & Hers finds itself competing more directly with pharmaceutical giants like Novo Nordisk and Eli Lilly. The potential easing of peptide regulations could provide a distinct competitive advantage and a new avenue for growth.
Regulatory Debate and Skepticism
Despite the market's optimistic reaction, the regulatory path forward is not guaranteed. The July advisory panel only provides recommendations; the process for broader access would proceed slowly from there. Some experts have expressed skepticism about relaxing rules for peptides that they consider unproven. Peter Lurie, a former FDA official, characterized the potential shift as "a profound threat" to the agency's established standards. Conversely, Scott Brunner of the Alliance for Pharmacy Compounding argued that any regulatory adjustment should be viewed strictly as "a supply chain issue."
Investors are currently speculating on future possibilities, as Hims & Hers has not yet launched a peptide product or provided a timeline or revenue projections for this potential category. The company states it is merely evaluating options that would align with FDA regulations, making the upcoming earnings report a key milestone for assessing the platform's capacity to absorb new therapeutic categories.
The stock's rally reflects market optimism about the long-term implications of the FDA's regulatory review. However, the ultimate impact will depend on the advisory panel's conclusions, subsequent FDA decisions, and the company's ability to execute its strategy in an evolving regulatory environment.
